What are the targeted therapy options to treat relapsed acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Targeted therapeutic options for AML include the following [25] :

  • FLT3-TKD mutation – Gilteritinib
  • FLT3-ITD mutation – Gilteritinib, or a hypomethylating agent (azacitidine or decitabine) + sorafenib
  • IDH1 mutation - Ivosidenib
  • IDH2 mutation - Enasidenib
  • CD33-positive AML - Gemtuzumab ozogamicin

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!